Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 18Recruiting 6Not yet recruiting 4Active not recruiting 4Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Recurrence 1Aumolertinib 1

Interventions

Carboplatin 34Pemetrexed 27Drug Therapy 22Cisplatin 22osimertinib 19aflutinib 11Paclitaxel 11pembrolizumab 10Surgical Procedures, Operative 10Docetaxel 10tislelizumab 9Radiotherapy 8Magnetic Resonance Spectroscopy 8anlotinib 7Specimen Handling 7Bevacizumab 7130-nm albumin-bound paclitaxel 7toripalimab 6cemiplimab 6Immunotherapy 6sintilimab 5ensartinib 5durvalumab 5Radiosurgery 5Platinum Compounds 5Nivolumab 5trametinib 4aumolertinib 4Observation 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Non-Small-Cell Lung × aumolertinib × Clear all
NCT06752408 2024-12-30

ANOTHER

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
316 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06463171 2024-06-17

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
108 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡